Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials

Mattia Rediti, Aranzazu Fernandez-Martinez, David Venet, Françoise Rothé, Katherine A. Hoadley, Joel S. Parker, Baljit Singh, Jordan D. Campbell, Karla V. Ballman, David W. Hillman, Eric P. Winer, Sarra El-Abed, Martine Piccart, Serena Di Cosimo, William Fraser Symmans, Ian E. Krop, Roberto Salgado, Sherene Loi, Lajos Pusztai, Charles M. Perou, Lisa A. Carey, Christos Sotiriou

Open source

DOI: 10.1038/s41467-023-42635-2
Published: 2023-11-03
Container: Nature Communications
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41467-023-42635-2,
  title = {Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials},
  author = {Mattia Rediti and Aranzazu Fernandez-Martinez and David Venet and Françoise Rothé and Katherine A. Hoadley and Joel S. Parker and Baljit Singh and Jordan D. Campbell and Karla V. Ballman and David W. Hillman and Eric P. Winer and Sarra El-Abed and Martine Piccart and Serena Di Cosimo and William Fraser Symmans and Ian E. Krop and Roberto Salgado and Sherene Loi and Lajos Pusztai and Charles M. Perou and Lisa A. Carey and Christos Sotiriou},
  year = {2023},
  journal = {Nature Communications},
  doi = {10.1038/s41467-023-42635-2},
  url = {https://doi.org/10.1038/s41467-023-42635-2}
}

RIS

TY  - JOUR
TI  - Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials
AU  - Mattia Rediti
AU  - Aranzazu Fernandez-Martinez
AU  - David Venet
AU  - Françoise Rothé
AU  - Katherine A. Hoadley
AU  - Joel S. Parker
AU  - Baljit Singh
AU  - Jordan D. Campbell
AU  - Karla V. Ballman
AU  - David W. Hillman
AU  - Eric P. Winer
AU  - Sarra El-Abed
AU  - Martine Piccart
AU  - Serena Di Cosimo
AU  - William Fraser Symmans
AU  - Ian E. Krop
AU  - Roberto Salgado
AU  - Sherene Loi
AU  - Lajos Pusztai
AU  - Charles M. Perou
AU  - Lisa A. Carey
AU  - Christos Sotiriou
PY  - 2023
JO  - Nature Communications
DO  - 10.1038/s41467-023-42635-2
UR  - https://doi.org/10.1038/s41467-023-42635-2
ER  -

APA

Rediti, M., Fernandez-Martinez, A., Venet, D., Rothé, F., Hoadley, K. A., Parker, J. S., Singh, B., Campbell, J. D., Ballman, K. V., Hillman, D. W., Winer, E. P., El-Abed, S., Piccart, M., Cosimo, S. D., Symmans, W. F., Krop, I. E., Salgado, R., Loi, S., Pusztai, L., Perou, C. M., Carey, L. A., & Sotiriou, C. (2023). Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials. Nature Communications. https://doi.org/10.1038/s41467-023-42635-2

Source records

crossref · retrieved 2026-09-26T19:59:55.877Z